Cue Biopharma Inc. (NASDAQ: CUE)
$0.93
+0.0020 ( +0.21% ) 279.9K
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
Market Data
Open
$0.93
Previous close
$0.93
Volume
279.9K
Market cap
$45.34M
Day range
$0.90 - $0.97
52 week range
$0.85 - $4.89
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jan 04, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |
10-q | Quarterly Reports | 75 | Nov 03, 2023 |
8-k | 8K-related | 12 | Sep 14, 2023 |
4 | Insider transactions | 1 | Aug 29, 2023 |
4 | Insider transactions | 1 | Aug 16, 2023 |
10-q | Quarterly Reports | 76 | Aug 08, 2023 |
4 | Insider transactions | 1 | Jul 25, 2023 |
4 | Insider transactions | 1 | Jul 25, 2023 |